Navigation Links
Dendreon Announces Election of Ian Clark and Pedro Granadillo to Board of Directors
Date:10/12/2009

SEATTLE, Oct. 12 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN) today announced that Ian Clark and Pedro Granadillo have been elected to the Company's Board of Directors. Mr. Clark is currently head of global product strategy and chief marketing officer at Roche, Pharma Division, and, beginning January 1, 2010, he will be chief executive officer and head of North American commercial operations at Genentech, a wholly-owned member of the Roche Group. Mr. Granadillo, now retired, was most recently senior vice president of global manufacturing and human resources at Eli Lilly & Company.

"We are pleased to welcome Ian and Pedro to Dendreon's Board of Directors. Their industry leadership experience commercializing significant oncology products and managing large scale pharmaceutical manufacturing facilities make them ideal additions to our Board of Directors as we expand from a research organization into a commercial enterprise," said Mitchell H. Gold, M.D., president and chief executive officer of Dendreon. "Their commercial expertise will strengthen the existing team at Dendreon as we prepare for U.S. Food and Drug Administration approval and the launch of PROVENGE® (sipuleucel-T) next year."

Mr. Clark previously was executive vice president of commercial operations and senior vice president of oncology commercial operations for Genentech's BioOncology business unit, which focused on global commercialization of the company's diverse oncology pipeline, including Avastin®, Rituxan® and Herceptin®. Prior to his time at Genentech, Mr. Clark was president of Novartis Canada and chief operating officer of Novartis United Kingdom. Mr. Clark received a B.S. in biological sciences from Southampton University in the United Kingdom.

Mr. Granadillo worked at Eli Lilly & Company fo
'/>"/>

SOURCE Dendreon Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Dendreon Completes Target Enrollment of 500 Patients in Phase 3 IMPACT Study of Provenge(R) For Advanced Prostate Cancer
3. Dendreon Presents Data Correlating the Cumulative Potency of PROVENGE(R) to Overall Survival
4. Dendreon Presents Preclinical Data Demonstrating Activity of Trp-p8 agonist, D-3263, in Benign Prostatic Hyperplasia
5. Dendreon Initiates Phase 2 Trial of PROVENGE in Patients With Localized Prostate Cancer Prior to Surgery
6. Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October
7. Dendreon to Hold a Conference Call Today at 9:00 AM ET to Provide an Update on Interim Results of Phase 3 PROVENGE IMPACT Trial
8. Dendreon Announces Interim Data From Phase 3 PROVENGE IMPACT Trial
9. Dendreon Presents Integrated Analysis of Clinical Data from NEUVENGE Trials at Chemotherapy Foundation Symposium
10. Dendreon to Hold a Conference Call Tomorrow at 9:00 AM ET to Discuss Final Results of Phase 3 PROVENGE IMPACT Trial
11. Dendreon Initiates Phase 1 Clinical Trial of Small Molecule Targeting TRPM8 in Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... , Oct. 22, 2014   Reproductive Medicine ... leader in the field of infertility, presents new ... embryonic screening. The research abstract, released during the ... Medicine (ASRM) meeting in Honolulu, Hawaii ... single gene defect (SGD) pre-implantation genetic diagnosis (PGD). ...
(Date:10/22/2014)... Calif. , Oct. 22, 2014  Paper ... products, has developed APLS ® Body Guard ... minimizes the spread of bacteria and virus while ... APLS Body Guard Bio features a rugged, external ... edges that create a leak-proof inner chamber that ...
(Date:10/22/2014)... A new report by Allied ... Form, End user, Application and Geography) - Size, Share, ... Opportunities, Segmentation and Forecast, 2013 - 2020", considers commercial ... key trends tracked, it is anticipated that the market ... 2020, registering a CAGR of 6.2% from 2014 to ...
Breaking Medicine Technology:New IVF Research Highlights Improved Genetic Screening Approach To Help Parents Have Healthier Babies 2New IVF Research Highlights Improved Genetic Screening Approach To Help Parents Have Healthier Babies 3New, State-Of-The-Art Body Bag Minimizes The Spread Of Bacteria And Virus 2Global Disposable Gloves Market Expected to Grow to $7.9 Billion by 2020 - Allied Market Research 2Global Disposable Gloves Market Expected to Grow to $7.9 Billion by 2020 - Allied Market Research 3Global Disposable Gloves Market Expected to Grow to $7.9 Billion by 2020 - Allied Market Research 4
... (Nasdaq: BIOD ) today announced positive top-line ... product candidates, BIOD-123 and BIOD-125 -- two proprietary ultra-rapid-acting ... BIOD-123 and BIOD-125 achieved the Company,s target pharmacokinetic, pharmacodynamic ... BIOD-123 favored as lead product candidate to advance to ...
... 13, 2012  AATAC, AACSA, and SKYROCK retailers can expect ... sale to the general public. A marketing and distribution ... retailers to participate in the resale of this product ... counter top space alongside such products as 5-Hour Energy, ...
Cached Medicine Technology:Biodel Reports Positive Top-Line Results from Study of Experimental Ultra-Rapid-Acting Insulin Formulations 2Biodel Reports Positive Top-Line Results from Study of Experimental Ultra-Rapid-Acting Insulin Formulations 3Biodel Reports Positive Top-Line Results from Study of Experimental Ultra-Rapid-Acting Insulin Formulations 4Biodel Reports Positive Top-Line Results from Study of Experimental Ultra-Rapid-Acting Insulin Formulations 5Biodel Reports Positive Top-Line Results from Study of Experimental Ultra-Rapid-Acting Insulin Formulations 6Strategic Product Deployment Announcement: Clotamin 2
(Date:10/22/2014)... October 22, 2014 For Dr. Iris Hunter, ... money; it’s an extension of her life’s mission. Her extensive ... as the owner of FirstLight HomeCare, make it clear that ... to me that my work makes a difference in the ... entrepreneurial spirit, so after much research, I felt ready to ...
(Date:10/22/2014)... October 22, 2014 Hay House is pleased ... Addiction and Upgrade Your Life (Paperback; $10.82) written by the ... & Recovery. This book is meant to help readers ... life of recovery. , Recovery 2.0 is not the ... Recovery 2.0 is a guide for what comes next. ...
(Date:10/22/2014)... Losing Weight Your Body’s Way , In a world where ... it certainly can be difficult to choose the right weight ... by doing it the healthy way? Set aside the fads ... body, exercise regularly, and choose foods with the most nutritional ... need to exercise more and eat less. Despite the number ...
(Date:10/22/2014)... Steven Reinberg HealthDay ... Infants who quickly add weight and length may be showing ... suggests. In adults, certain genes have been linked to ... proportionate gains in fat and lean muscle, the researchers said. ... heavier and taller. By ages 2 and 3, however, these ...
(Date:10/22/2014)... Oct. 21, 2014 (HealthDay News) -- Measures taken by ... in Ebola-ravaged Liberia may have limited the spread of ... report. The Firestone Natural Rubber Co. provides health ... residents of nearby densely populated communities. Between Aug. ... suspected Ebola cases among those 80,000 people. That incidence ...
Breaking Medicine News(10 mins):Health News:Dr. Iris Hunter to Host Grand Opening of FirstLight HomeCare Tomorrow 2Health News:Hay House Announces The Official Release of Recovery 2.0: Move Beyond Addiction and Upgrade Your Life 2Health News:Hay House Announces The Official Release of Recovery 2.0: Move Beyond Addiction and Upgrade Your Life 3Health News:ReductionGuruMD Presents Ways to Improve Your Weight Loss Results 2Health News:Tall, Heavy 1-Year-Olds May Be at Risk for Obesity Later, Study Finds 2Health News:Tire Company Sets Standard for Ebola Care in Liberia: CDC 2
... Women having children at older ages and the growing ... in the birth of twins: In 2009, one in every ... compared with one in every 53 in 1980. The ... at the 14th Congress of the International Society of Twin ...
... Computer scientists and biologists in the Data ... a rare collaboration between the two very different fields ... modern medicine. Their unique partnership has uncovered a new ... of human tissue to its corresponding biological function. The ...
... research team led by scientists from Singapore Immunology Network ... (A*STAR) discovered that a special class of fatty molecules ... immune cells. This study sheds light on how recognition ... infection, allergic reactions, autoimmune diseases and cancer. More importantly, ...
... -- Measles vaccines don,t increase the risk of febrile seizures ... study. Febrile seizures are brief, fever-related convulsions that are ... or other seizure disorders. The study, conducted by the ... Centers for Disease Control and Prevention, looked at data from ...
... 2, 2012)Scientists at Fox Chase Cancer Center have uncovered more ... makes new proteins can lead to blood and other cancers. ... Annual Meeting 2012 on Monday, April 2, may one day ... "These findings help explain how mutations in one class of ...
... research developments to reprogram scar tissue resulting from ... at the Frontiers in CardioVascular Biology (FCVB) 2012 meeting, held ... of Imperial College in London. In a keynote ... described as a "game changer" with the potential to revolutionise ...
Cached Medicine News:Health News:Seeing double: 1 in 30 babies born in US is a twin 2Health News:From beaker to bits: Collaboration creates computational model of human tissue 2Health News:From beaker to bits: Collaboration creates computational model of human tissue 3Health News:From beaker to bits: Collaboration creates computational model of human tissue 4Health News:A*STAR scientists discover special class of natural fats stimulates immune cells to fight diseases 2Health News:Measles Vaccines Won't Raise Seizure Risk in Young Kids: Study 2Health News:Researchers uncover new clues to the development of blood and other cancers 2Health News:Transforming scar tissue into beating hearts: The next instalment 2Health News:Transforming scar tissue into beating hearts: The next instalment 3Health News:Transforming scar tissue into beating hearts: The next instalment 4
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: